Johnson & Johnson reported 10% sales growth in Q1 2026, but adjusted earnings per share (EPS) declined by 2.5% year-over-year, with operational growth at 5.3%. Despite management's goal of double-digit growth by the decade's end, consensus forecasts a more modest EPS compound annual growth rate of around 6%. The stock's high valuation multiples, including 30.4 times earnings and 36.0 times free cash flow, raise concerns, especially with upcoming patent expirations like Stelara. Key growth areas to watch include oncology and medical technology sectors. Due to these factors, the stock is maintained at a 'Hold' rating amid overvaluation worries.
The Goldman Sachs Future Health Care Equity ETF (GDOC) gained momentum after positive news from its largest holding, Eli Lilly (LLY), whose price target was raised by JPMorgan. GDOC has returned 11.8% over the past three months, recovering from earli...
RoseNose Investing Group highlights Nvidia and PepsiCo as undervalued stocks with strong growth and reliable dividends, recommending them as buys. Shell is considered fairly valued with a 4% dividend yield, suggesting buying on dips but not aggressiv...
Jim Cramer advises investors to view the recent market rotation as a buying opportunity for high-quality stocks that were unfairly sold off due to institutional portfolio shifts. He highlights companies such as Johnson & Johnson, PepsiCo, Starbucks, ...
